Skip to Main Content
Try STAT+ TODAY
Trending:
The Obesity Revolution
STAT+
Health
Biotech
Subscribe Now To access exclusive content, subscribe to STAT+
View Latest View the latest STAT+ stories
Pharmalot
STAT+

Novo Nordisk to pay $58 million for not complying with an FDA program

  • Ed Silverman

By Ed Silverman Sept. 5, 2017

Reprints
Andrew Harnik/AP

File this under “What were they thinking?”

Novo Nordisk (NVO) has agreed to pay more than $58 million to settle allegations that it failed to adequately alert doctors one of its diabetes drugs may be associated with thyroid cancer, a step that was required by regulators at the time its medicine was approved.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

About the Author Reprints

Ed Silverman

Ed Silverman

Pharmalot Columnist, Senior Writer

Ed Silverman covers the pharmaceutical industry.

Tags

‘A game-changer’: How Vertex delivered on cystic fibrosis
‘A game-changer’: How Vertex delivered on cystic fibrosis
Flawed herpes testing leads to many false positives —…
Flawed herpes testing leads to many false positives — and needless suffering
Do CRISPR enthusiasts have their head in the sand…
Do CRISPR enthusiasts have their head in the sand about the safety of gene editing?
Study finds same small rise in breast cancer risk…
Study finds same small rise in breast cancer risk in many forms of hormonal birth control
Patient groups balk at former AstraZeneca official negotiating U.K.-India…
Patient groups balk at former AstraZeneca official negotiating U.K.-India free trade deal
Altimmune’s obesity drug fails to stand out from blockbuster…
Altimmune’s obesity drug fails to stand out from blockbuster treatments in early data

Recommended Stories